To the Editor:
Complex diseases, including asthma, have genetic and environmental origins. Genome-wide association studies have identified multiple genes for the development of asthma, yet they only explain a limited proportion of asthma heritability. Interactions between genetic predisposition and exposure to passive smoking might explain in part the hidden heritability of childhood asthma. However, to date, this approach has not been reported for the discovery of interactions between genes and tobacco smoke exposure.
We performed a genome-wide interaction study (GWIS) on childhood asthma to identify genes that interact with 2 well-known environmental risk factors for childhood-onset asthma: in utero and childhood tobacco smoke exposure. We meta-analyzed interaction results from 9 studies participating in the GABRIEL consortium1 including more than 6,000 subjects of European descent. We replicated our findings in 4 independent studies including more than 13,000 subjects. Childhood-onset asthma was defined as asthma diagnosed by a doctor before the age of 16 years, which is consistent with the definition in the GABRIEL consortium.1 In utero tobacco smoke exposure was defined as “exposure to maternal tobacco smoking at any time during pregnancy.” Childhood tobacco smoke exposure was defined as “exposure to passive tobacco smoking at any time from birth until 16 years of age.” Details on the number of subjects, the design of the individual studies, and outcome and exposure definitions are provided in Tables E1 to E4 in this article's Online Repository at www.jacionline.org.
The effects of in utero tobacco smoke exposure and childhood tobacco smoke exposure were analyzed separately. All individual studies were analyzed by using a logistic regression model containing the genetic effect, the effect of tobacco smoke exposure, and an interaction term indicating the interaction between the genetic effect and tobacco smoke exposure. Further methodological considerations on GWISs and details on the statistical analyses are described in this article's Online Repository at www.jacionline.org.
For in utero tobacco smoke exposure, the discovery genome-wide meta-analysis consisted of 2,654 cases and 3,073 control subjects derived from 7 studies (see Table E1). Overall, in utero tobacco smoke exposure increased the risk of childhood-onset asthma (see Fig E1 in this article's Online Repository at www.jacionline.org). A total of 536,705 single nucleotide polymorphisms (SNPs) were included in the interaction meta-analysis. Fig E2 in this article's Online Repository at www.jacionline.org shows the Manhattan plot. We identified 27 SNPs in the discovery sample with a P value of less than 10−4 based on the fixed effect model (Table I and see Table E5 in this article's Online Repository at www.jacionline.org). Findings did not reach genome-wide significance but were consistent over all studies included, and no significant heterogeneity across studies was present (P value Q-statistic < .05). Four of these SNPs on chromosome 10 were in high linkage disequilibrium with each other in the discovery meta-analysis (r2 = 0.82-0.96). The most prominent marker was located on chromosome 18 near EPB41L3 (Forest plot, see Fig E3 in this article's Online Repository at www.jacionline.org). Table E6 in this article's Online Repository at www.jacionline.org shows the associations in exposed and nonexposed subjects. EPB41L3 belongs to the protein 4.1 family of membrane-associated proteins, is involved in cell-cell junctions,2 and might play a role in apoptosis.3 The literature shows that in utero tobacco smoke exposure affects the expression of genes involved in biological processes, such as cell proliferation and apoptosis, and influences lung development of the child in general.4 Our data suggest that this effect of in utero smoke exposure might potentially occur through mechanisms involving EPB41L3 (see the additional text in this article's Online Repository).
Table I.
Ch | SNP | Closest gene∗ | Type | Discovery |
Replication |
||||
---|---|---|---|---|---|---|---|---|---|
N† | ORint‡ | Pf | N† | ORint‡ | Pf | ||||
1 | rs1674877 | — | Intergenic | 2654 | 0.51 | 2.19 × 10−5 | 201 | 1.06 | .89 |
2 | rs4670230 | FAM82A1 | Intronic | 2654 | 1.94 | 2.10 × 10−5 | 201 | 0.78 | .51 |
2 | rs12624082 | GALNT13 | Intronic | 2654 | 1.78 | 3.22 × 10−5 | 697 | 1.00 | .98 |
2 | rs11684139 | GALNT13 | Intronic | 2654 | 1.77 | 7.57 × 10−5 | 697 | 0.85 | .35 |
2 | rs729454 | — | Intergenic | 2654 | 1.67 | 9.52 × 10−5 | 697 | 1.13 | .45 |
3 | rs3856848 | IL5RA | Intronic | 2654 | 1.96 | 5.32 × 10−6 | 201 | 0.59 | .19 |
4 | rs7682603 | — | Intergenic | 2247 | 0.54 | 1.19 × 10−5 | 562 | 1.20 | .29 |
5 | rs1990977 | RNU6ATAC2P | Intergenic | 2654 | 2.12 | 7.79 × 10−5 | 697 | 0.88 | .60 |
5 | rs4700239 | — | Intergenic | 2654 | 2.15 | 6.39 × 10−5 | 562 | 0.78 | .34 |
6 | rs6456433 | — | Intergenic | 2654 | 1.99 | 7.99 × 10−5 | 562 | 0.71 | .15 |
6 | rs14398 | WDR46 | Nonsynonymous | 2654 | 0.45 | 5.44 × 10−5 | 562 | 1.77 | .01 |
8 | rs360968 | — | Intergenic | 2654 | 0.54 | 5.05 × 10−5 | 697 | 0.93 | .72 |
9 | rs943856 | — | Intergenic | 2654 | 0.59 | 4.94 × 10−5 | 697 | 0.70 | .04 |
10 | rs11006296 | — | Intergenic | 2654 | 2.01 | 3.70 × 10−5 | 562 | 0.84 | .47 |
10 | rs1407696 | PDCD4 | Intronic | 2654 | 0.57 | 2.36 × 10−5 | 66 | 0.58 | .34 |
10 | rs7079511 | SHOC2 | Intronic | 2654 | 0.58 | 3.24 × 10−5 | 697 | 0.98 | .91 |
10 | rs521674 | ADRA2A | Upstream | 2654 | 0.57 | 5.35 × 10−5 | 562 | 1.16 | .45 |
10 | rs602618 | ADRA2A | Downstream | 2654 | 0.57 | 5.63 × 10−5 | 562 | 1.15 | .45 |
11 | rs1123991 | OR51E2 | Synonymous | 2654 | 0.50 | 6.51 × 10−5 | 697 | 0.68 | .11 |
11 | rs3898589 | CNTN5 | Intronic | 2654 | 1.83 | 6.11 × 10−5 | 562 | 1.17 | .40 |
11 | rs10892848 | CNTN5 | Intronic | 2654 | 1.82 | 5.72 × 10−5 | 697 | 1.07 | .71 |
12 | rs706793 | ACCN2 | Intronic | 2654 | 1.66 | 3.62 × 10−5 | 697 | 0.75 | .07 |
13 | rs7321384 | C13orf35 | Intronic | 2654 | 0.58 | 9.82 × 10−5 | 697 | 0.92 | .63 |
16 | rs8051325 | ANKS4B | Intronic | 2654 | 0.47 | 8.37 × 10−5 | 562 | 0.80 | .37 |
18 | rs8094633 | EPB41L3 | Intergenic | 2654 | 2.13 | 4.29 × 10−5 | 201 | 2.87 | .03 |
21 | rs858003 | KCNJ6 | Intronic | 2654 | 1.81 | 8.50 × 10−5 | 697 | 1.00 | 1.00 |
22 | rs9613256 | CTA-211A9.5 | Within noncoding gene | 2654 | 0.59 | 5.44 × 10−5 | 562 | 1.11 | .60 |
Ch, Chromosome; ORint, odds ratio interaction; Pf, P value, fixed effect.
Closest gene within range of 500 kb of the position of the SNP.
Number of studies and cases included in meta-analysis.
Additive genetic model.
For childhood tobacco smoke exposure, the discovery genome-wide meta-analysis consisted of 3,048 cases and 3,509 control subjects derived from 9 studies (see Table E1). Overall, childhood tobacco smoke exposure increased the risk of childhood-onset asthma (see Fig E1). A total of 538,233 SNPs were included in the interaction meta-analysis. Fig E4 in this article's Online Repository at www.jacionline.org shows the Manhattan plot. We identified 35 SNPs in the discovery sample with a P value of less than 10−4 based on the fixed effect model. Four of these SNPs were excluded because they showed heterogeneity, and the P value of the random effect was greater than 10−4. Findings did not reach genome-wide significance. Table II and Table E7 (see this article's Online Repository at www.jacionline.org) the results for the top SNPs. Seven SNPs on chromosome 5 (except rs2312164) were in high linkage disequilibrium with each other in the discovery studies (r2 = 0.83-1.00).
Table II.
Ch | SNP | Closest gene∗ | Type | Discovery |
Replication |
||||
---|---|---|---|---|---|---|---|---|---|
N† | ORint‡ | Pf | N† | ORint‡ | Pf | ||||
1 | rs2026604 | S100A7L2 | Downstream | 3048 | 1.44 | 7.49 × 10−5 | 1003 | 0.83 | .17 |
2 | rs10184453 | — | Intergenic | 3048 | 1.53 | 8.85 × 10−5 | 1003 | 1.18 | .30 |
2 | rs895565 | — | Intergenic | 3048 | 1.53 | 7.26 × 10−5 | 1003 | 1.18 | .30 |
2 | rs11126185 | — | Intergenic | 3048 | 0.67 | 6.81 × 10−6 | 868 | 1.22 | .16 |
3 | rs4234677 | CTD-2230D16.1 | Within noncoding gene | 3048 | 0.65 | 6.57 × 10−5 | 261 | 1.58 | .22 |
3 | rs264096 | MAGI1 | Intronic | 3048 | 0.62 | 6.93 × 10−6 | 396 | 0.89 | .63 |
3 | rs17239426 | KCNAB1 | Intronic | 3048 | 0.58 | 7.28 × 10−5 | 1003 | 1.18 | .39 |
4 | rs1425551 | IRF2 | Intronic | 3048 | 1.40 | 6.92 × 10−5 | 1003 | 0.98 | .86 |
5 | rs162036 | MTRR | Nonsynonymous | 3048 | 0.60 | 8.26 × 10−5 | 1003 | 1.14 | .45 |
5 | rs7719963 | — | Intergenic | 3048 | 0.56 | 3.06 × 10−5 | 868 | 0.89 | .59 |
5 | rs7447231 | — | Intergenic | 3048 | 1.55 | 8.36 × 10−6 | 868 | 0.85 | .31 |
5 | rs10155635 | — | Intergenic | 3048 | 1.56 | 7.55 × 10−6 | 261 | 0.62 | .11 |
5 | rs10038850 | — | Intergenic | 3048 | 1.53 | 1.51 × 10−5 | 261 | 0.41 | .04 |
5 | rs10479335 | — | Intergenic | 3048 | 1.52 | 5.98 × 10−5 | 868 | 0.85 | .29 |
5 | rs2312164 | — | Intergenic | 3048 | 1.42 | 7.18 × 10−5 | 1003 | 0.82 | .14 |
5 | rs13357477 | — | Intergenic | 3048 | 1.58 | 3.59 × 10−6 | 868 | 0.83 | .24 |
5 | rs12719549 | — | Intergenic | 3048 | 1.57 | 4.61 × 10−6 | 868 | 0.82 | .21 |
5 | rs4607330 | — | Intergenic | 3048 | 1.59 | 2.70 × 10−6 | 868 | 0.85 | .31 |
6 | rs441463 | LYRM4 | Intronic | 3048 | 1.41 | 4.91 × 10−5 | 1003 | 0.90 | .42 |
6 | rs1575472 | PACRG | Intronic | 3048 | 1.78 | 1.37 × 10−5 | 1003 | 1.51 | .06 |
7 | rs17544971 | GRB10 | Intronic | 3048 | 1.70 | 8.12 × 10−5 | 868 | 1.26 | .28 |
9 | rs4977750 | MTAP | Nonsense-mediated decay transcript | 3048 | 0.61 | 1.91 × 10−5 | 1003 | 0.93 | .66 |
13 | rs4769148 | — | Intergenic | 2445 | 0.67 | 4.45 × 10−5 | 261 | 0.72 | .21 |
13 | rs12874184 | — | Intergenic | 3048 | 1.98 | 8.75 × 10−5 | 868 | 1.18 | .50 |
13 | rs16972472 | — | Intergenic | 3048 | 1.79 | 9.59 × 10−5 | 868 | 0.79 | .32 |
14 | rs10141836 | OR11G2 | Upstream | 3048 | 0.70 | 8.89 × 10−5 | 1003 | 0.90 | .41 |
15 | rs2602923 | C15orf41 | Intronic | 3048 | 1.61 | 4.52 × 10−5 | 1003 | 1.19 | .33 |
16 | rs13331814 | ZP2 | Intronic | 3048 | 0.62 | 8.38 × 10−5 | 868 | 0.85 | .34 |
19 | rs11085080 | PLIN5 | Intronic | 3048 | 0.51 | 6.30 × 10−5 | 1003 | 1.12 | .63 |
20 | rs6077755 | PSMF1 | Upstream | 3048 | 1.52 | 6.65 × 10−6 | 1003 | 1.11 | .47 |
X | rs6641609 | PRKX | Intronic | 1939 | 0.49 | 3.43 × 10−5 | 261 | 1.90 | .15 |
Ch, Chromosome; ORint, odds ratio interaction; Pf, P value, fixed effect.
Closest gene within range of 500 kb of the position of the SNP.
Number of cases and control subjects included in the meta-analysis.
Additive genetic model.
The most prominent marker was located on chromosome 6 in PACRG (parkin coregulated gene; Forest plot, see Fig E5 in this article's Online Repository at www.jacionline.org). Table E8 in this article's Online Repository at www.jacionline.org shows the associations in exposed and nonexposed subjects. PACRG is located next to and has an overlapping promoter region with parkin 2 (PARK2).5 The gene has been associated with leprosy and parkinsonian diseases and has an important role in motile cilia function and cilia morphogenesis.2,6 PACRG is relatively highly expressed in the trachea and nasal mucosa. Ciliary dysfunction might impair mucus clearance from the airways and has been shown to affect asthma severity. Our data suggest that changes in ciliary function particularly affect the development of asthma in children exposed to passive tobacco smoke.
The genes that have been reported previously to interact with tobacco smoke exposure with respect to asthma development (ie, TNF,7 GSTP1,7 and ADAM338) were not among our most significant hits. This can be explained by the fact that the genetic variants in these candidate gene studies have a strong main effect on asthma development. Bouzigon et al9 showed a more pronounced effect of the 17q21 region on the development of early-onset asthma in children with early-life tobacco smoke exposure than in those without. The genetic effect of these markers in our GWIS showed a similar direction, but the interaction was not significant.
This study on childhood asthma is the first hypothesis-free GWIS specifically aiming to identify SNPs that interact with tobacco smoke exposure in disease development. We found suggestive evidence for an interaction between rs8094633 on chromosome 18 near EPB41L3 and in utero tobacco smoke exposure and an interaction between rs1575472 on chromosome 6 in PACRG and childhood tobacco smoke exposure. The SNPs found have not been identified previously in general genome-wide association studies on childhood asthma. Interestingly, the SNPs interacting with in utero and childhood tobacco smoke exposure were different and were not involved in the same pathway (see Fig E6 in this article's Online Repository at www.jacionline.org). Interactions between these SNPs and tobacco smoke exposure in utero and in childhood might explain part of the missing heritability of asthma. Future research needs to confirm these findings and further unravel the biological pathways.
Acknowledgments
For acknowledgments, see this article's Online Repository at www.jacionline.org.
Footnotes
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
The GABRIEL study (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community) was supported by the European Commission, contract number 018996, under the Integrated Program LSH-2004-1.2.5-1 and the Wellcome Trust (WT084703MA). Funding of the individual studies is described in this article's Online Repository at www.jacionline.org.
Disclosure of potential conflict of interest: A. J. Henderson has been supported by grants from the Medical Research Council (UK) and from the Wellcome Trust. F. Nyberg is employed by AstraZeneca. G. Pershagen has been supported by one or more grants from the European Union and the Swedish Research Council. D. Jarvis has been supported by one or more grants from the European Union. M. Wjst has been supported by one or more grants from the European Union (FP6). F. Kauffmann has been supported by one or more grants from the ANR French National Agency of research, the French Agency for Environmental and Occupational Health Safety, Inserm, and Merck Sharp and Dohme. E. Von Mutius has been supported by one or more grants from the European Commission; is an Associate Editor of the Journal of Allergy and Clinical Immunology; and has consultancy arrangements with GlaxoSmithKline, Novartis, ALK-Abelló, and Astellas Pharma. M. J. Ege has been supported by grants from the European Commission and from Deutsche Forschungsgemeinschaft. P. Pare has been supported by one or more grants from Allergen NCE. S. Lau has been supported by one or more grants from the German Research Foundation, is a member of a Drug Monitoring Committee, has consultancy arrangements with Symbiopharm and Allergopharm, and has received one or more payments for lecturing from or is on the speakers' bureau for Symbiopharm, Dannone, GlaxoSmithKline, and Novartis. T. Keil has received one or more grants from or has one or more grants pending with EU-FP7. Y. Lee has received one or more grants from or has one or more grants pending with the European Union and the German Research Foundation. M. Kabesch has been supported by one or more grants from the European Union, the German Ministry of Education and Research, and the German Research Foundation and has received one or more payments for lecturing from or is on the speakers' bureau for the European Respiratory Society, the European Academy of Allergy and Clinical Immunology, the American Thoracic Society, Novartis, and GlaxoSmithKline. M. Farrall has been supported by one or more grants from and has received support for travel from EU FP7. G. H. Koppelman has been supported by one or more grants from the European Union and has received one or more grants from or has one or more grants pending with the Netherlands Asthma Foundation, Stichting Asthma Bestrijding. The rest of the authors declare that they have no relevant conflicts of interest.
Supplementary data
References
- 1.Moffatt M.F., Gut I.G., Demenais F., Strachan D.P., Bouzigon E., Heath S. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010;363:1211–1221. doi: 10.1056/NEJMoa0906312. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.UniProt Consortium Reorganizing the protein space at the Universal Protein Resource (UniProt) Nucleic Acids Res. 2012;40(Database issue):D71–D75. doi: 10.1093/nar/gkr981. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Dafou D., Grun B., Sinclair J., Lawrenson K., Elizabeth C., Benjamin E.C. Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia. 2010;12:579–589. doi: 10.1593/neo.10340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Maritz G.S., Harding R. Life-long Programming implications of exposure to tobacco smoking and nicotine before and soon after birth: evidence for altered lung development. Int J Environ Res Public Health. 2011;8:875–898. doi: 10.3390/ijerph8030875. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.West A.B., Lockhart P.J., O'Farell C., Farrer M.J. Identification of a novel gene linked to parkin via a bi-directional promoter. J Mol Biol. 2003;326:11–19. doi: 10.1016/s0022-2836(02)01376-1. [DOI] [PubMed] [Google Scholar]
- 6.Wilson G.R., Wang H.X., Egan G.F., Robinson P.J., Delatycki M.B., O'Bryan M.K. Deletion of the Parkin co-regulated gene causes defects in ependymal ciliary motility and hydrocephalus in the quakingviable mutant mouse. Hum Mol Genet. 2010;19:1593–1602. doi: 10.1093/hmg/ddq031. [DOI] [PubMed] [Google Scholar]
- 7.Panasevich S., Lindgren C., Kere J., Wickman M., Pershagen G., Nyberg F. Interaction between early maternal smoking and variants in TNF and GSTP1 in childhood wheezing. Clin Exp Allergy. 2010;40:458–467. doi: 10.1111/j.1365-2222.2010.03452.x. [DOI] [PubMed] [Google Scholar]
- 8.Reijmerink N.E., Kerkhof M., Koppelman G.H., Gerritsen J., De Jongste J.C., Smit H.A. Smoke exposure interacts with ADAM33 polymorphisms in the development of lung function and hyperresponsiveness. Allergy. 2009;64:898–904. doi: 10.1111/j.1398-9995.2009.01939.x. [DOI] [PubMed] [Google Scholar]
- 9.Bouzigon E., Corda E., Aschard H., Dizier M.H., Boland A., Bousquet J. Effect of 17q21 variants and smoking exposure in early-onset asthma. N Engl J Med. 2008;359:1985–1994. doi: 10.1056/NEJMoa0806604. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.